Therapeutic Peptide

BPC-157

Popular in biohacking communities but evidence is almost entirely from animal studies.

VEGF angiogenesisNO/eNOS signalingFAK-paxillin pathwayGrowth factor modulation

38 C

Evidence Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice. It has gained significant popularity in biohacking and athletic communities for purported tissue repair and anti-inflammatory properties. However, the evidence base consists almost entirely of animal studies, with no published human clinical trials.

Mechanism of Action

Proposed mechanisms include upregulation of growth factor expression (EGF, VEGF, FGF), promotion of angiogenesis via the NO/eNOS system, modulation of the FAK-paxillin pathway for cell migration, and anti-inflammatory effects through cytokine modulation. These mechanisms are primarily characterized in rat models.

Evidence Base

Over 100 animal studies (primarily rodent) demonstrate tissue healing effects across tendons, muscles, ligaments, gut mucosa, and bone. No published human RCTs. No FDA-approved indication. Evidence is pre-clinical only, which is reflected in the low human trial evidence score.

Gene Pathway Detail

In animal models, BPC-157 upregulates VEGF and FGF2 expression at injury sites, promoting angiogenesis and tissue repair. FAK-paxillin pathway activation supports cell migration and wound healing. eNOS modulation affects nitric oxide-mediated vasodilation and blood flow to damaged tissue. These pathways are monitorable but have not been validated in human transcriptomic studies.

mRNA Monitoring Insight

Biomeme's platform could theoretically monitor VEGF, FGF, and inflammatory gene targets in BPC-157 users. However, the absence of human validation data means expected gene expression changes are extrapolated from animal models. This makes mRNA monitoring particularly valuable — it could provide some of the first human molecular data for this peptide.

Safety Considerations

No human safety data from controlled trials. Generally reported as well-tolerated in anecdotal user reports. Manufactured in research chemical and compounding settings with variable quality control. The lack of human pharmacokinetic and toxicology data is the primary safety concern.

FAQ

Why does BPC-157 only get a C grade?

Despite its popularity, BPC-157 has zero published human clinical trials. All evidence comes from animal models. The C grade reflects this honest assessment — the mechanism is plausible, but the human evidence simply doesn't exist yet.

Quick Facts

Category: Therapeutic Peptide
Score: 38/100 (C)
Gene Pathways: 4 characterized

Sources

[1] BPC-157 Review — J Physiology Paris 2017

Compare Others

Monitor Your Peptide Response.

Biomeme's transcriptomic platform tracks molecular pathway engagement so you know if your therapy is working.